Previous 10 | Next 10 |
2023-07-13 17:25:28 ET Gainers: ACADIA Pharmaceuticals ( ACAD ) +29% . Intuitive Machines ( LUNR ) +25% . Atara Biotherapeutics ( ATRA ) +5% . Xilio Therapeutics ( XLO ) +5% . Alector ( ALEC ) +3% . Losers: Theseus ...
Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer Favorable preliminary safety profile for XTX101 observed at the recommended Phase 2 dose of 150 mg once every six weeks WALTHAM, Mass., May 25, 2023 (GLOBE NEW...
2023-05-09 08:54:44 ET Xilio Therapeutics press release ( NASDAQ: XLO ): Q1 GAAP EPS of -$0.83 beats by $0.06 . Cash and cash equivalents were $93.3 million as of March 31, 2023, compared to $120.4 million as of December 31, 2022. For further details see: ...
Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor activity data for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in the second quarter of 2023 Ended first quarter of 2023 with $93.3 ...
2023-04-11 09:30:29 ET Innovative Eyewear ( LUCY ) +129% on launching the first ChatGPT enabled smart eyewear. ZeroFox Holdings ( ZFOX ) +63% on partnering with Google Cloud to disrupt phishing attacks and malicious URLs.WW International WW +38% as Sequence deal closes, Goldman move...
WALTHAM, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the Compensation Committee of the Board of Directors granted a non-quali...
Xilio Therapeutics press release ( NASDAQ: XLO ): Q4 GAAP EPS of -$0.82 misses by $0.08 . Ended 2022 with $120.4 million in cash and cash equivalents; continue to anticipate cash runway into the second quarter of 2024 For further details see: Xilio Therapeutics GAAP ...
Initial clinical data from XTX101, XTX202 and XTX301 clinical trials anticipated in 2023 XTX202, a tumor-activated IL-2, demonstrated preliminary clinical pharmacodynamic evidence of tumor-selective activation, providing initial clinical platform validation Anticipate initiating...
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced its participation in the following upcoming investor conferences: Cowen 43 ...
WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in Citi...
News, Short Squeeze, Breakout and More Instantly...
Xilio Therapeutics Inc. Company Name:
XLO Stock Symbol:
NASDAQ Market:
Xilio Therapeutics Inc. Website:
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Sh...
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-a...